Drugs Affecting Blood and Blood Formation Practice Questions

Q: What is the primary mechanism of action of heparin?

It enhances the action of antithrombin III.. **It enhances the action of antithrombin III.** - Heparin binds to **antithrombin III (ATIII)**, causing a conformational change that increases its affinity for clotting factors, particularly **thrombin (factor IIa)** and **factor Xa** [1, 2]. - This augmentation of ATIII's inhibitory activity is crucial for its anticoagulant effect, preventing the formation and propagation of clots [1].*It directly inhibits thrombin without cofactors.* - Directly inhibiting thrombin without cofactors describes the mechanism of direct thrombin inhibitors like **dabigatran**, not heparin. - Heparin requires the presence of **antithrombin III** as a cofactor for its anticoagulant activity [1].*It increases platelet aggregation.* - Heparin is an **anticoagulant** that works by preventing clot formation, which includes inhibiting platelet aggregation in some contexts, but its primary mechanism is not to increase it. - Medications that increase platelet aggregation are typically **procoagulant** agents, which is the opposite effect of heparin.*It has a half-life of 12-24 hours.* - Heparin, specifically **unfractionated heparin**, has a relatively short half-life, typically around **1 to 2 hours**, necessitating continuous intravenous infusion or frequent subcutaneous injections. - A half-life of 12-24 hours is more characteristic of some **low molecular weight heparins** or vitamin K antagonists like **warfarin**.

Q: Which of the following statements about warfarin is false?

Warfarin does not cross the placenta. ***Warfarin does not cross the placenta*** - Warfarin **rapidly crosses the placenta**, leading to fetal exposure and potential teratogenic effects, such as **fetal warfarin syndrome**. - This characteristic makes warfarin generally **contraindicated during pregnancy**, especially in the first trimester. *Half-life is 25 to 60 hours* - The half-life of warfarin is indeed relatively long, ranging from approximately **25 to 60 hours**, which contributes to its once-daily dosing. - This prolonged half-life means that changes in dosing take several days to reach a **new steady-state** and affect the International Normalized Ratio (INR). *Inhibits vitamin K dependent clotting factor synthesis* - Warfarin functions as a **vitamin K antagonist**, inhibiting the hepatic synthesis of vitamin K-dependent clotting factors **II, VII, IX, and X**. - It achieves this by blocking **vitamin K epoxide reductase**, an enzyme essential for reactivating vitamin K. *Contraindicated in patients with severe hepatic failure* - Warfarin is primarily metabolized in the **liver** by cytochrome P450 enzymes, and its clotting factors are synthesized in the liver. - Therefore, **severe hepatic failure** can impair both warfarin metabolism and the production of clotting factors, leading to an increased risk of bleeding and making it a contraindication.

Q: In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

Prevention of venous thrombosis and pulmonary embolism. ***Prevention of venous thrombosis and pulmonary embolism*** - Anticoagulants are highly effective in inhibiting the formation and extension of **venous thrombi**, thereby directly preventing **deep vein thrombosis (DVT)** and **pulmonary embolism (PE)**. - The mechanism of action targets the **coagulation cascade**, directly reducing the risk of these venous thromboembolic events, which are a major indication for anticoagulant therapy. *Prevention of recurrences of myocardial infarction* - While anticoagulants may play a secondary role, **antiplatelet agents** (e.g., aspirin, clopidogrel) are the primary therapy for preventing recurrent myocardial infarction, as **arterial thrombi** are predominantly platelet-rich. - Anticoagulants are used in specific high-risk situations post-MI (e.g., **atrial fibrillation**, left ventricular thrombus) but are not generally considered the primary preventive strategy. *Cerebrovascular accident* - The benefit of anticoagulants for stroke prevention is primarily significant in cases of **cardioembolic stroke** (e.g., due to **atrial fibrillation**) where they prevent clot formation in the heart. - For non-cardioembolic **ischemic strokes** (e.g., thrombotic or lacunar), antiplatelet agents are generally preferred for secondary prevention. *Retinal artery thrombosis* - **Retinal artery thrombosis** is often caused by **arterial atherosclerosis** and **embolism** from the carotid arteries or heart, where antiplatelet agents are typically primary. - The role of anticoagulants here is limited to specific causes like **atrial fibrillation** or in patients already on anticoagulation for other indications.

Q: Warfarin's mechanism of action is

Inhibiting Vitamin K dependent carboxylation. ***Inhibiting Vitamin K dependent carboxylation*** - **Warfarin** acts as an antagonist to **vitamin K**, competitively inhibiting the enzyme **vitamin K epoxide reductase**. - This prevents the **gamma-carboxylation** of vitamin K-dependent clotting factors (II, VII, IX, X, and proteins C and S), rendering them biologically inactive. *Chelating calcium ions* - **Calcium ions** are essential cofactors in the coagulation cascade, but warfarin does not directly affect their concentration or chelate them. - Anticoagulants that chelate calcium, such as **citrate**, are typically used *in vitro* (e.g., in blood collection tubes), not systemically. *Inhibiting antithrombin III activity* - This mechanism describes the action of **heparin** and its derivatives, which enhance the natural anticoagulant activity of **antithrombin III**. - Warfarin's primary action is on vitamin K metabolism, not on antithrombin III potentiation. *Inhibiting thrombin activity* - Direct thrombin inhibitors (**DTIs**), such as dabigatran and argatroban, directly bind to and inhibit the activity of **thrombin (factor IIa)**. - Warfarin's action is upstream in the coagulation cascade, affecting the synthesis of multiple clotting factors, including prothrombin (the precursor to thrombin).

Q: Heparin activates which factor(s)?

Antithrombin III. ***Antithrombin III*** - **Heparin** exerts its anticoagulant effect primarily by binding to and activating **antithrombin III (ATIII)**. - Activated **ATIII** then inactivates several coagulation factors, most notably **thrombin (Factor IIa)** and **Factor Xa**, preventing clot formation. *Factor IIa* - **Factor IIa** (thrombin) is a **target** of the heparin-antithrombin III complex, not directly activated by heparin. - Heparin-ATIII complex **inhibits** Factor IIa, preventing its procoagulant effects. *Factor IXa* - While **Factor IXa** is also inhibited by the **heparin-antithrombin III complex**, it is not directly activated by heparin. - The inhibition of Factor IXa contributes to heparin's overall anticoagulant effect, particularly in the intrinsic pathway. *Factor Xa* - **Factor Xa** is a **primary target** of the **heparin-antithrombin III complex**, leading to its inactivation. - Heparin does not activate Factor Xa; rather, it facilitates its rapid **inhibition** by antithrombin III.

Q: All of the following drugs can prolong bleeding time except which of the following?

Multivitamins containing Vitamin K. ***Multivitamins containing Vitamin K*** - **Vitamin K** is essential for the synthesis of **coagulation factors** (II, VII, IX, X) in the liver. - Supplementation with Vitamin K can **shorten bleeding time** by promoting proper clot formation, thereby counteracting any tendency for prolonged bleeding. *Cephalosporins* - Certain **cephalosporins**, particularly those with a methylthiotetrazole side chain (e.g., Cefamandole, Cefoperazone), can **inhibit vitamin K-dependent clotting factor synthesis** and interfere with platelet function. - This interference can lead to a **prolonged bleeding time** and an increased risk of hemorrhage. *Methylxanthines* - **Methylxanthines** such as **theophylline** and caffeine, can **inhibit platelet aggregation** and reduce **adenosine diphosphate (ADP)-induced platelet responsiveness**. - This **antiplatelet effect** can result in a **prolonged bleeding time**. *Anti-depressants* - Many **antidepressants**, especially **Selective Serotonin Reuptake Inhibitors (SSRIs)**, can **interfere with serotonin uptake by platelets**. - Serotonin is crucial for **platelet aggregation**, and its diminished uptake can lead to **platelet dysfunction** and a **prolonged bleeding time**.

Q: Which of the following is an antiplatelet drug?

Clopidogrel. ***Clopidogrel*** - Clopidogrel is an **antiplatelet agent** that works by irreversibly inhibiting the **P2Y12 ADP receptor** on platelets, preventing platelet activation and aggregation. - It is commonly used for the prevention of **thrombotic events** in patients with acute coronary syndrome, stroke, or peripheral artery disease. *Tranexamic acid* - Tranexamic acid is an **antifibrinolytic drug** that inhibits the activation of plasminogen to plasmin, thereby preventing the breakdown of fibrin clots. - It is primarily used to **reduce bleeding** in various conditions such as heavy menstrual bleeding, surgical procedures, and trauma. *Streptokinase* - Streptokinase is a **thrombolytic agent** that acts by forming a complex with plasminogen, leading to its conversion to plasmin, which then breaks down fibrin clots. - It is used to dissolve existing blood clots in conditions such as acute myocardial infarction, pulmonary embolism, and deep vein thrombosis. *Hirudin* - Hirudin is a direct **thrombin inhibitor** originally isolated from the salivary glands of medicinal leeches. - It directly binds to and inactivates thrombin, thereby preventing the conversion of fibrinogen to fibrin and inhibiting clot formation.

Q: What is the mechanism of action of ticagrelor?

P2Y12 inhibitor. ***P2Y12 inhibitor*** - Ticagrelor is an **oral antiplatelet agent** that works by reversibly binding to the **P2Y12 receptor** on platelets. - This binding prevents adenosine diphosphate (ADP) from activating the P2Y12 receptor, which is crucial for **platelet aggregation** and **thrombus formation**. *PAR1 inhibitor* - **PAR1 inhibitors** (e.g., vorapaxar) block the thrombin receptor on platelets, leading to antiplatelet effects. - This mechanism is distinct from ticagrelor's action on the P2Y12 receptor. *PAR1 activator* - Activating **PAR1** would promote platelet aggregation and activation, which is the opposite effect of an antiplatelet medication like ticagrelor. - This mechanism would increase the risk of thrombosis. *P2Y12 activator* - Activating the **P2Y12 receptor** would lead to increased platelet aggregation and is not the mechanism of action for an antiplatelet drug. - Drugs that activate P2Y12 would promote the formation of blood clots.

Q: Oral anticoagulants are monitored by what?

Prothrombin time (PT) - Monitors extrinsic pathway. ***Prothrombin time (PT) - Monitors extrinsic pathway*** - **Oral anticoagulants**, such as **warfarin**, inhibit the synthesis of **vitamin K-dependent clotting factors** (II, VII, IX, X), which primarily affect the **extrinsic pathway** of coagulation. - The **PT** measures the time it takes for plasma to clot after the addition of **tissue factor**, assessing the function of the extrinsic and common pathways, making it the standard test for monitoring warfarin therapy. - In clinical practice, **INR (International Normalized Ratio)** is derived from PT to standardize results across laboratories. *Bleeding time (BT) - Assesses platelet function* - **Bleeding time** assesses **platelet function** and **vascular integrity**, not the efficacy of oral anticoagulants. - It is an older test, largely replaced by **platelet function analyzers** and **platelet aggregation studies** for assessing platelet disorders. *Coagulation time (CT) - General clotting assessment* - **Coagulation time** is a general, less sensitive measure of overall clotting and is not specific enough to accurately monitor the effects of oral anticoagulants. - It is a historical test with limited clinical utility for anticoagulant management. *Partial thromboplastin time (PTT) - Monitors intrinsic pathway* - The **partial thromboplastin time (PTT)** assesses the **intrinsic and common pathways** of coagulation, primarily used to monitor **heparin therapy**. - While oral anticoagulants can affect some factors in the intrinsic pathway, the **PT** is the more sensitive and appropriate test for monitoring their effect.

Question 1

What is the primary mechanism of action of heparin?

Accepted Answer

It enhances the action of antithrombin III.

Answer

It increases platelet aggregation.

Answer

It directly inhibits thrombin without cofactors.

Answer

It has a half-life of 12-24 hours.

Question 2

Which of the following statements about warfarin is false?

Accepted Answer

Warfarin does not cross the placenta

Answer

Half-life is 25 to 60 hours

Answer

Inhibits vitamin K dependent clotting factor synthesis

Answer

Contraindicated in patients with severe hepatic failure

Question 3

In which of the following clinical conditions does the use of anticoagulants provide maximum benefit?

Accepted Answer

Prevention of venous thrombosis and pulmonary embolism

Answer

Prevention of recurrences of myocardial infarction

Answer

Prevention of cerebrovascular accident (stroke)

Answer

Retinal artery thrombosis

Question 4

Warfarin's mechanism of action is

Accepted Answer

Inhibiting Vitamin K dependent carboxylation

Answer

Chelating calcium ions

Answer

Inhibiting antithrombin III activity

Answer

Inhibiting thrombin activity

Question 5

Which of the following anticoagulants is the preferred choice for safe use in pregnancy?

Accepted Answer

Low molecular weight heparin (LMWH)

Answer

Warfarin

Answer

Unfractionated heparin (UFH)

Answer

Direct oral anticoagulants (DOACs)

Question 6

Heparin activates which factor(s)?

Accepted Answer

Antithrombin III

Answer

Factor IXa

Answer

Factor Xa

Answer

Factor IIa

Question 7

All of the following drugs can prolong bleeding time except which of the following?

Accepted Answer

Multivitamins containing Vitamin K

Answer

Methylxanthines

Answer

Anti-depressants

Answer

Cephalosporins

Question 8

Which of the following is an antiplatelet drug?

Accepted Answer

Clopidogrel

Answer

Streptokinase

Answer

Hirudin

Answer

Tranexamic acid

Question 9

What is the mechanism of action of ticagrelor?

Accepted Answer

P2Y12 inhibitor

Answer

PAR1 activator

Answer

P2Y12 activator

Answer

PAR1 inhibitor

Question 10

Oral anticoagulants are monitored by what?

Accepted Answer

Prothrombin time (PT) - Monitors extrinsic pathway

Answer

Bleeding time (BT) - Assesses platelet function

Answer

Coagulation time (CT) - General clotting assessment

Answer

Partial thromboplastin time (PTT) - Monitors intrinsic pathway

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?